Voluven® 6%

​​HES 130/0.4 in 0.9% sodium chloride solution - The latest generation of starches.

Voluven® – The most widely used synthetic colloid

  • 6% hydroxyethyl starch 130/0.4 in 0,9% sodium chloride solution
  • Derived from waxy maize starch (potato starch is not bioequivalent*)
  • Iso-oncotic solution – suitable for volume replacement
  • Provides both initial and medium-term volume effects (4-6 h)
  • Millions of patients worldwide treated since 1999
  • Supported by extensive clinical evidence

* Lehmann et al., Drugs R D 2007; 8(4): 229-240

Please refer to the nationally registered and approved SmPC.

The signs/names marked with ® are registered trademarks of the Fresenius Group in selected countries.

  • Voluven® is indicated for treatment of hypovolemia due to acute blood loss when crystalloids alone are not considered sufficient.
  • Hypovolemia is associated with disturbances in macro- and microcirculation.
  • Macro- and microcirculation disturbances give rise to diminished organ blood flow and decreased oxygen supply to various organs, and finally to functional organ failure.

Please refer to the nationally registered and approved SmPC.

The signs/names marked with ® are registered trademarks of the Fresenius Group in selected countries.

Efficacy
  • Significantly greater volume effect and superior haemodynamic stability vs. crystalloids*1,2,3
  • More favorable fluid balance vs. crystalloids*1,2,4
  • Reduced inflammatory response in surgical settings5,6
Safety
  • Comparable blood loss and transfusion requirements to controls**7
  • Renal function and need for renal replacement therapy is comparable to other fluid alternatives7,8,9,10
  • No evidence for increased mortality vs. controls**7,9,10
  • * The maximum daily dosage used in Feldheiser et al. 2013 (≤ 50 ml/kg BW) may not be covered by locally applicable SmPCs.
  • ** Controls: colloid or crystalloid solution other than HES 130/0.4
  • * The maximum daily dosage used in Feldheiser et al. 2013 (≤ 50 ml/kg BW) may not be covered by locally applicable SmPCs​

Please refer to the nationally registered and approved SmPC.

1) Feldheiser et al., Br J Anaesth 2013; 110(2): 231-240*
2) Zhang et al., Clinics (Sao Paulo) 2012; 67(10): 1149-1155
3) Fas et al., Intensive Care Med 2012; 38: 151
4) Lindroos et al., Acta Anaesthesiol Scand 2013; 57(6): 729-736
5) Yang et al., Chin Med J 2011; 124(10): 1458-1464
6) Volta et al., Anesthesiology 2007; 106(1): 85-91
7) Van der Linden et al., Anesth Analg 2013; 116(1): 35-48
8) Mahmood et al., Br J Surg 2007; 94(4): 427-433
9) Gillies et al., Br J Anaesth 2014; 112(1); 25-34
10) Martin et al., Anesthesiology 2013; 118(2): 387-394

  • Please note that this product may not be available in all countries due to different registration status. Additionally, approved indications, contraindications, side effects, warnings and all other product characteristics may differ between countries.
  • Therefore, always the text of the nationally registered and approved product information is binding!
  • Furthermore, country specific regulatory considerations affect the information we can provide on our products.
  • If you require any information, please contact your local organization.
  • The Important Safety Guidance might differ in your respective country depending on decision of your local regulatory authority. To receive the local Important Safety Guidance in addition please visit the respective country homepage or contact the respective local Fresenius Kabi organization.
  • Please refer to the nationally registered and approved SmPC. ​